Overall rank by patents
#27,977
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
ADS Therapeutics Llc
USPTO PatentsView assignee record - 9 granted patents across 4 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
9
Total patents granted
4
CPC technology areas
10.2
Avg claims per patent
-
5-year filing velocity
The verdict
ADS holds 9 US patents across 4 technology areas, rank #27,977 of 50,000 tracked assignees.
- #27,977
- of 50,000 US assignees by volume
- Top 75%
- by Innovation Score (27.8/100)
- 10.2
- avg claims per patent
Portfolio overview
ADS Therapeutics Llc has been granted 9 US utility patents between 2020 and 2025, placing ADS Therapeutics Llc at rank #27,977 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 10.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, ADS Therapeutics Llc is one of the more focused assignees in the PatentsView dataset. By volume, ADS sits between Adare Pharmaceuticals USA, Inc. (9 patents, rank #27,973) and Adventist Health System/sunbelt, Inc. (9 patents, rank #27,981) - the closest US assignees by grant volume. The composite Innovation Score of 27.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. ADS Therapeutics Llc's 10.2 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ADS Therapeutics Llc against peers pursuing similar technology classes.
Who files at ADS's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Adare Pharmaceuti…
ADARE PHARMACEUTICALS USA, INC.
9 patents
- Adasa
ADASA Inc.
9 patents
- ADRC KR
ADRC. CO. KR
9 patents
- Adrenomed
ADRENOMED AG
9 patents
- Adswizz
ADSWIZZ INC.
9 patents
- Advanced Analog T…
ADVANCED ANALOG TECHNOLOGY, INC.
9 patents
- Advancing B V
ADVANCING TECHNOLOGIES B.V.
9 patents
- Adventist Health…
ADVENTIST HEALTH SYSTEM/SUNBELT, INC.
9 patents
- ADS Therapeutics ◀
ADS Therapeutics LLC
9 patents
What this shows ADS holds 9 patents at rank #27,977, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near ADS
By rank, the assignees closest to #27,977 in granted patent volume.
- Adare Pharmaceuticals USA, Inc. #27,973 · 9 patents
- Adasa Inc. #27,974 · 9 patents
- ADRC. Co. KR #27,975 · 9 patents
- Adrenomed Ag #27,976 · 9 patents
- Adswizz Inc. #27,978 · 9 patents
- Advanced Analog Technology, Inc. #27,979 · 9 patents
- Advancing Technologies B.v. #27,980 · 9 patents
- Adventist Health System/sunbelt, Inc. #27,981 · 9 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in ADS's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
ADS's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
28 Top 75% higher than 25% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 11.1% |
| 2021 | 3 | 33.3% |
| 2022 | 1 | 11.1% |
| 2024 | 3 | 33.3% |
| 2025 | 1 | 11.1% |
Which technologies does ADS Therapeutics Llc patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Simple
Frequently Asked Questions
How many patents does ADS Therapeutics Llc hold?
ADS Therapeutics Llc holds 9 US granted patents filed between 2020 and 2025, spanning 4 technology areas.
What is ADS Therapeutics Llc's Innovation Score?
ADS Therapeutics Llc has an Innovation Score of 27.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does ADS Therapeutics Llc focus on?
ADS Therapeutics Llc's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 9 patents. The company has filed patents in 4 CPC subclasses total.
Is ADS Therapeutics Llc's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for ADS Therapeutics Llc.
What does claim depth mean for ADS Therapeutics Llc's patents?
ADS Therapeutics Llc's patents average 10.2 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the ADS Therapeutics Llc patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
ADS's 9 grants land it in the top 75% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - ADS ranks #27,977 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.